Samsung Life Science Fund Invests in Arbor Biotechnologies to Develop Next-Generation Genetic Medicines
- Investment strengthens Samsung’s commitment to enabling advanced biopharmaceutical technologies to bring meaningful impact to patients worldwide
- Investment to support Arbor Biotechnologies’ rapidly advancing pipeline of novel gene editing therapeutics addressing genetic conditions of the liver and central nervous system (CNS)
INCHEON, Korea – October 30, 2025 – Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, today announced an equity investment in Arbor Biotechnologies, Inc., a leading clinical stage biotechnology company discovering and developing the next generation of in vivo genetic medicines.
The investment strengthens Samsung’s commitment to enabling advanced biopharmaceutical technologies such as genetic medicines, and supports Arbor’s mission to translate cutting-edge gene editing technologies into therapeutics that offer life-changing potential for patients with serious diseases with high unmet medical need.
“Arbor Biotechnologies’ represents a best-in-class gene editing company with the potential to transform how genetic diseases are treated,” said Yun Cheol Kim, Vice President of Research and Early Development at Samsung Bioepis. “Our investment reflects our commitment to advancing breakthrough technologies that can bring meaningful impact to patients worldwide.”
“We are thrilled to welcome Samsung as a strategic investor,” said Devyn Smith, Ph.D., CEO of Arbor Biotechnologies. “Their support reinforces the strength of our science, the rigor of our execution, and the potential of our pipeline and will help us accelerate the development of transformative therapies for patients with severe genetic diseases.”
About Arbor Biotechnologies, Inc.
Arbor Biotechnologies™, a clinical stage, next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions – from the ultra-rare to the most common genetic diseases. The company’s unique suite of optimized gene editors, which is capable of approaches ranging from gene knockout, excisions, reverse transcriptase editing, and large gene insertion, goes beyond the limitations of early editing technologies to unlock access to new gene targets and has fueled a robust pipeline of first-in-class assets focused on diseases of high unmet need. With Arbor’s clinical program, ABO-101 for the treatment of primary hyperoxaluria type 1, the company continues to focus its research and development efforts on genomic diseases of the liver and CNS for which there are no existing functional cures. For more information, please visit: arbor.bio.
About Samsung Ventures
Samsung Venture Investment Corporation was established to promote promising small and medium-sized companies engaging in the development of new technologies. Our collaboration is based on managerial know-how and trust, and actively investing in future-oriented businesses based on new and innovative technologies that are expected to serve as new growth engines. Please visit our website for more detail: https://www.samsungventure.co.kr/english_main.do .
Media Contact – Samsung Bioepis
Yoon Kim, yoon1.kim@nullsamsung.com
Anna Nayun Kim, nayun86.kim@nullsamsung.com
Media Contact – Arbor Biotechnologies
Peg Rusconi, Deerfield Group